digitalstudios

About digitalstudios

This author has not yet filled in any details.
So far digitalstudios has created 4663 blog entries.

Minimally Invasive Procedure Making Treatment Possible for More People with Normal Pressure Hydrocephalus | By Dan Levangie, President and CEO of CereVasc

Dan Levangie writes: CereVasc’s eShunt System is sparking interest across [...]

By |2024-11-22T12:34:38+00:00November 22, 2024|3rd Party Medical Device Industry News|Comments Off on Minimally Invasive Procedure Making Treatment Possible for More People with Normal Pressure Hydrocephalus | By Dan Levangie, President and CEO of CereVasc

The Role of Endovascular Specialists in the Multidisciplinary Approach to Postpartum Hemorrhage | By Dr. Adam Power, Co-Founder and CMO, Front Line Medical Technologies

Postpartum hemorrhage (PPH) continues to challenge obstetric care despite ongoing [...]

By |2024-11-21T11:42:52+00:00November 21, 2024|3rd Party Medical Device Industry News|Comments Off on The Role of Endovascular Specialists in the Multidisciplinary Approach to Postpartum Hemorrhage | By Dr. Adam Power, Co-Founder and CMO, Front Line Medical Technologies

The Future of Precision Medicine Delivering ROI for the Healthcare Industry | By: Gary Turner, Managing Director, Additive Manufacturing, Ricoh USA, Inc.

Gary Turner asks: What do orthopedic surgery and additive manufacturing [...]

By |2024-11-19T11:41:46+00:00November 19, 2024|3rd Party Medical Device Industry News|Comments Off on The Future of Precision Medicine Delivering ROI for the Healthcare Industry | By: Gary Turner, Managing Director, Additive Manufacturing, Ricoh USA, Inc.

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial (“INVINCIBLE-3 Study”) in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Phase 1/2 data showed a median overall survival (“mOS”) of [...]

By |2024-11-18T16:33:33+00:00November 18, 2024|3rd Party Medical Device Industry News|Comments Off on Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial (“INVINCIBLE-3 Study”) in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Go to Top